IMV102 / Immunofoco - LARVOL DELTA

Dose-Escalation/Expansion Study of iMagic in Relapsed/Refractory Hematologic Malignancies (clinicaltrials.gov) - P1 | N=30 | Not yet recruiting | Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd

New P1 trial • Hematological Malignancies • Lymphoma • Multiple Myeloma • Oncology

IMV102, an in vivo BCMA-targeting CAR-T therapy, achieves durable tumor control in multiple myeloma models (AACR 2026) - "Treatment was well tolerated, with no significant weight loss observed.ConclusionsIMV102 enables efficient and selective in vivo generation of functional BCMA CAR-T cells, resulting in potent and durable antitumor activity in multiple myeloma models. These results pave the way for further clinical investigation."

CAR T-Cell Therapy • IO biomarker • Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology • CD4 • CD8 • IFNG

Immunofoco Presents Preclinical Data for IMV102, an In Vivo CAR-T Candidate, Demonstrating Durable Tumor Control at the AACR 2026 (PRNewswire) - "The data demonstrate that IMV102 achieved potent and durable anti-tumor activity in multiple myeloma models, highlighting its potential to address key limitations of conventional CAR-T therapies....In vivo, IMV102 induced CAR-T cell generation and achieved potent and durable tumor inhibition in two multiple myeloma xenograft models (H929-Luc and MM.1S-Luc, human PBMC-reconstituted mice). Tumor burden was significantly reduced. Body weight remained stable throughout the study, with no significant safety signals observed."

Preclinical • Multiple Myeloma

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Malignancies • Multiple Myeloma • Oncology

A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - P1/2 | N=30 | Not yet recruiting | Sponsor: Suzhou Immunofoco Biotechnology Co., Ltd

New P1/2 trial • Hematological Malignancies • Multiple Myeloma • Oncology